What Happened
- Commerce and Industry Minister Piyush Goyal stated that "re-balancing" the India-US trade deal is possible given "changed circumstances," signalling India's willingness to adjust the terms of the Bilateral Trade Agreement (BTA) framework
- India described itself as being in "wait-and-watch" mode while seeking the "best possible opportunities" — indicating a calibrated, interest-driven negotiating posture rather than unconditional acceptance of US terms
- The statement came in the context of the US-India Interim Trade Framework (February 2026), which set tariffs at 18% and launched a $500 billion purchasing commitment, but left significant issues — including non-tariff barriers, services, and intellectual property — for the full BTA to resolve
- The changed circumstances referenced include the evolving US-China trade tensions (which give India strategic leverage), the Iran conflict's impact on energy markets, and the India-EU FTA's completion
Static Topic Bridges
India's Trade Negotiating Philosophy: Strategic Autonomy in Commerce
India has historically been a cautious multilateral trader. At the WTO, India has used its large domestic market and political leverage to defend food security (agricultural subsidies, Public Stockholding under Agreement on Agriculture), access to affordable medicines (TRIPS flexibilities), and tariff policy space (high bound rates on manufactured goods). India walked out of RCEP negotiations in 2019, citing concerns about Chinese import flooding and inadequate services access in competing markets. This pattern — engage but protect key domestic interests — defines India's approach to the India-US BTA. Goyal's "wait-and-watch" language is consistent with this posture: India will negotiate but will not make unilateral concessions.
- WTO Agreement on Agriculture (AoA): India defends the right to provide food subsidies under "public stockholding" — a recurring flash point with the US and developed countries
- TRIPS Agreement (WTO): India has invoked compulsory licensing and TRIPS flexibilities to produce affordable generic medicines — the US has long sought stronger IP protections in India
- RCEP: Regional Comprehensive Economic Partnership; India chose not to join (2019) over concerns about Chinese goods flooding and inadequate services market access
- India's bound tariff rates vs. applied rates: Bound rates (WTO ceiling) average ~34% for agricultural goods; applied rates are much lower, giving India flexibility to raise tariffs without WTO violation
- "Special and Differential Treatment" (SDT) at WTO: India has championed SDT for developing countries — a principle the US has sought to limit
Connection to this news: Goyal's signal about rebalancing reflects India's established pattern — accept the overall framework but seek specific carve-outs for politically sensitive sectors (agriculture, dairy, e-commerce) while leveraging India's growing strategic weight.
The Structure of the India-US Bilateral Trade Agreement (BTA)
The India-US BTA framework, launched in February 2025, is structured as a two-phase agreement: an Interim Framework (Phase 1, effective April 2026) addressing tariff reduction and a purchasing commitment, followed by a comprehensive BTA (Phase 2, expected late 2026 or 2027) covering the full range of trade issues. The "changed circumstances" Goyal referred to likely include: the evolving geopolitical context (India's strategic value has risen as a China-alternative supply chain hub), the US's own legislative and business community pressure for market access in India (especially in agriculture and digital services), and India's leverage from its energy purchasing commitment. The interim deal slashed US tariffs on Indian goods from 50% to 18%, but Phase 2 negotiations will be the more contentious battle.
- Phase 1 (Interim Framework): Tariffs on Indian goods → 18%; India's $500 billion purchasing commitment (energy, aircraft, coking coal, precious metals, technology)
- Phase 2 (Full BTA): Addresses non-tariff barriers, IP, services and investment, labour, environment, government procurement, state-owned enterprises
- India's sensitive sectors in Phase 2: Dairy (India protects domestic dairy extensively), e-commerce (digital trade rules could affect India's data localisation policy), agricultural tariffs
- US priority demands in Phase 2: Medical device pricing regulation (India's price caps are a US business grievance), pharmaceutical data exclusivity (TRIPS-plus demands), agricultural market access
- India's leverage: Growing market of 1.4 billion consumers; $500 billion commitment already made; rising importance as China-alternative supply chain hub
Connection to this news: Goyal's "rebalancing" signal suggests India will use Phase 2 negotiations to push back on US demands in sensitive areas, while the "wait-and-watch" posture reflects India maintaining optionality — including the possibility of further delays if terms are unfavourable.
WTO Rules and Bilateral Trade Agreements: Legal Architecture
The WTO's Most Favoured Nation (MFN) principle requires members to extend the same tariff concessions to all WTO members (Article I of GATT). However, Article XXIV of GATT permits PTAs (Preferential Trade Agreements) and FTAs provided they cover "substantially all trade" and do not raise barriers against third parties. The India-US BTA, if concluded, would need to comply with Article XXIV requirements. Additionally, non-tariff barriers (NTBs) — which are the more contentious issues in India-US trade — are governed by the WTO's Technical Barriers to Trade (TBT) Agreement and the Sanitary and Phytosanitary (SPS) Agreement. India's NTB commitments under Phase 2 (medical devices, ICT, agriculture) are all subject to TBT/SPS disciplines.
- GATT Article XXIV: Legal basis for bilateral FTAs under WTO; requires "substantially all trade" coverage (typically >90% of tariff lines)
- MFN principle (GATT Article I): Once India reduces tariffs for the US under BTA, other WTO members can claim equivalent treatment — unless India grants US a formal FTA with WTO notification
- TBT Agreement: Governs technical regulations, standards, and conformity assessment procedures — covers medical device pricing and ICT import licensing
- SPS Agreement: Governs sanitary and phytosanitary measures (food safety, plant/animal health) — India's agricultural NTBs on US products are governed here
- India's e-commerce moratorium at WTO: India and South Africa have led developing country resistance to permanent duty-free e-commerce — the US-India BTA will likely require India to shift this position
Connection to this news: Phase 2 of the India-US BTA will essentially require India to navigate WTO disciplines while protecting domestic policy space — the "rebalancing" Goyal referenced is code for preserving this space through hard-fought sectoral negotiations.
Key Facts & Data
- India-US goods trade: ~$130 billion (2024-25); India surplus ~$32 billion
- US tariffs on Indian goods under Interim Agreement: 18% (from peak 50%)
- India's $500 billion purchasing commitment: Energy, aircraft, coking coal, precious metals, technology (5 years)
- Phase 1 effective: April 2026
- Phase 2 (comprehensive BTA): Expected late 2026 or 2027
- India's average applied MFN tariff: ~7.5% industrial; ~32-39% agricultural
- India's bound tariffs (WTO ceiling): Much higher than applied rates — allows tariff policy flexibility
- RCEP withdrawal: November 2019 (India chose not to join the Asia-Pacific megadeal)
- WTO TBT Agreement: Governs technical standards and regulations in trade
- India's medical device price caps: A recurring US grievance — Indian government caps prices of cardiac stents, knee implants under Drugs (Prices Control) Order, 2013
- India's data localisation policy (DPDP Act, 2023): Restricts cross-border data flows — a US digital trade concern